Takuma Hayashi

Takuma Hayashi (born 14 February 1969) is a Japanese doctor specializing in cancer genomic medicine and Gynecological tumor and virologist.Hayashi's work on viral vectors based on human immunodeficiency virus (HIV) genes led to the discovery of the construction of nucleic acid vaccine based on DNA or RNA. Hayashi is currently a professor and section head of Cancer Medicine at the National Hospital Organization Kyoto Medical Center and genetic medicine at Kyoto University Hospital Collaboration Cancer Genomic Medicine. Hayashi is also a medical researcher at the Clinical Research, Innovation and Education Center, Tohoku University Hospital (CRIETO).
==Early life and education==
Hayashi began his scientific and medical career at the Institute of Medical Science, The University of Tokyo where he completed a B.S. in biochemistry and Medicine. Hayashi went to complete her doctoral work in Medicine and Medical Science at the Institute of Medical Science, The University of Tokyo. Hayashi was awarded a Ph.D. (D.M.Sci) and MBBS by the Institute of Medical Science, The University of Tokyo.
== Career and research ==
After postdoctoral training, he got faculty position Lecture, at Massachusetts General Hospital (MGH)/Harvard Medical School (HMS) in 1997. He has been studying the antigen presentation system by Major Histocompatibility Gene Complex (MHC) class I with Lmp2/b1i-deficient mice, under the cooperation of Dr. Susumu Tonegawa (Nobel Laureate, M.I.T.). Hayashi identifies diagnostic biomarkers, LMP2/b1i, Cyclin B1 and Cyclin E, for malignant tumor, i.e. uterine leiomyosarcoma, and BRCA1 and Protein S100-A4|S100A4 for ovarian carcinoma. Hayashi focuses clinical therapy by using cancer genome medicine for patients with cancer and malignant tumors at Cancer Genomic Medicine, Kyoto University Hospital. Hayashi is also medical researcher at the Clinical Research, Innovation and Education Center, Tohoku University Hospital (CRIETO).
In a recent research letter published on the veterinary quarterly, Hayashi’s research group; scientists from Japan discovered that the mutation of spike glycoprotein in the severe acute respiratory syndrome coronavirus 2 (SARSCoV2) derived from farmed minks can also be found in the group of individuals with coronavirus disease (COVID19) and subsequently evade detection by our immune system.
Hayashi’s and his research group accentuates that mutations in SARSCoV2 that lead to generation of SARSCoV­ 2 subspecies have made humans and animals susceptible to infection through easy propagation in the host, thereby making it difficult to identify the effects of therapeutic agents or vaccines for COVID19.
==Awards==
* 2022 Winner: Takuma Hayashi, Newsweek BEST Doctor
* 2018 Winner: Takuma Hayashi, Prestigious Innovative Research Developers and Publishers (IRDP) Award 2018
* 2018 Winner: Takuma Hayashi, WC1803-103: Winner at World University Championship
* 2018 Winner: Takuma Hayashi, Winner at World Academic Championship-2018 in Medical Oncology
* 2009 Recipient: Takuma Hayashi, The 41st Ichimura Academic Prize Awarded by Prince Tomohito Mikasanomiya
==Publications==
* The protein tyrosine kinase Fyn activates transcription from the HIV promoter via activation of NFkB-like DNA-binding proteins.
* Elucidation of a conserved RNA stem-loop structure in the packaging signal of human immunodeficiency virus type 1.
* Human thioredoxin/adult T cell leukemia-derived factor activates the enhancer binding protein of human immunodeficiency virus type 1 by thiol redox control mechanism.
Category:Japanese people
Category:Japanese doctors
Category:1969 births